p-SCN-Bn-DOTA
p-SCN-Bn-DOTA can be used in radiopharmacy, targeted cancer therapy, and bioorthogonal chemistry, particularly in areas such as diagnostic imaging and personalized medicine.
DOTA can chelate divalent and trivalent cations, e.g. Gallium
| Catalogue | SC-3013 |
|---|---|
| Formula | C24H33N5O8S |
| CAS | 1020407-41-3 |
| MW | 551,62 |
| Appearance | white powder |
| Purity | >94% (HPLC-UV λ=254nm) |
| Solubility | Soluble in water |
| Size | 100mg / 500mg |
| Storage | Keep cool and dry. Protect from light and moisture. Store at - 20°C on arrival. |
Possible application of p-SCN-Bn-DOTA:
-
Radiopharmacy:
-
p-SCN-Bn-DOTA can be used in radiopharmacy, particularly in imaging (e.g., PET scans) or targeted cancer therapy. The DOTA group can be chelated with a radioactive isotope (e.g., Gallium-68 or Lutetium-177) to specifically visualize or treat tumors or other diseased tissues.
-
-
Targeted Therapy:
-
The p-SCN-Bn (aminobenzyl) group serves as a functional group that allows covalent binding to other molecules, such as monoclonal antibodies or peptides. These conjugates can then specifically bind to tumor cells and deliver a therapeutic effect, such as radiation with a radioactive isotope or the delivery of a cytostatic agent.
-
-
Bioorthogonal Chemistry:
-
p-SCN-Bn-DOTA can also be used in bioorthogonal chemistry to react specifically with other bioorthogonal molecules (e.g., Tetrazine groups). This allows for precise targeting and delivery of therapeutics to specific structures.
-
In summary, p-SCN-Bn-DOTA is primarily used for diagnostic imaging, targeted cancer therapy, and bioorthogonal labeling systems, where precise targeting of molecules is required.